The Association of Science and
Technology Centers (ASTC) has contracted SRI International (SRI) to
conduct an independent evaluation of the Communities for Immunity
(C4I) Project. The C4I Project, administered by ASTC in partnership
with the American Alliance of Museums (AAM) and the Network of the
National Library of Medicine (NLM) and supported by the Institute
of Museum and Library Services (IMLS) and the Centers for Disease
Control and Prevention (CDC), supports libraries, museums, and
their partners to engage local communities with the aim of
increasing COVID-19 vaccine confidence and, ultimately, of
improving community vaccination rates. The C4I Project also aims to
increase libraries’ and museums’ organizational capacity to partner
in addressing critical national and local issues. This new
emergency clearance request is for the study design and instruments
that SRI proposes to use in evaluating C4I Round 2 award
activities. Most of the proposed instruments are the same as those
used in the Round 1 data collection, which OMB approved on November
15, 2021, under OMB Control Number 3137-0129. In consultation with
OMB, IMLS has submitted two separate clearance requests to
accommodate two sequential timelines and some variation in
approach. Data collection activities for Round 1 activities were
scheduled for November through December, 2021, and those for Round
2 activities are scheduled for January through April, 2022. Very
brief surveys were appropriate for all Round 1 projects, which had
a lower per-project funding ceiling, whereas the higher per-project
funding ceiling in Round 2 is likely to result in more in-depth
project activities that warrant slightly expanded data collection
efforts. This proposed data collection fills an urgent need to
understand promising strategies for mitigating vaccine hesitancy
and improving vaccination-seeking behavior and vaccination rates in
communities around the country. More than 800,000 Americans have
died of COVID-19-related causes since February 2020 and, despite
widespread availability of the vaccine in the US, only 61 percent
of Americans of all ages nationwide are fully vaccinated. In a 2020
survey measuring potential acceptance of a COVID-19 vaccines, just
two-thirds (66%) of Americans said that they would definitely or
probably get vaccinated when a COVID-19 vaccine became available;
subsequent surveys have shown that vaccine hesitancy is a key
reason for this choice. Sources of vaccine hesitancy included
concerns that fast vaccine approval could reflect lowered quality
standards, concerns about the newness of mRNA vaccine development,
and misinformation circulated on social media—all despite evidence
that vaccines are safe to use. As COVID-19 continues to cause
severe illness and death, increasing vaccination rates in the U.S.
remains a top national priority. It is also vital to build
confidence among parents and caregivers in the recently approved
vaccine for children ages 5-11.
The project’s short
timeframe reflects the urgency of mitigating COVID-19 impacts,
particularly in disproportionately affected communities where the
project especially aims to make a difference. IMLS is seeking
approval for this collection by January 25, 2022, in order to
accelerate the timeline for sharing findings among IMLS
stakeholders and with broader national audiences.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.